• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    6/16/23 5:39:31 PM ET
    $AXDX
    $BACK
    $BFRI
    $CALC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care
    Get the next $AXDX alert in real time by email

    Gainers

    • Biofrontera (NASDAQ:BFRI) shares moved upwards by 52.3% to $0.67 during Friday's after-market session. Today's trading volume for this security ended up closing at 1.7 million shares, which is 2335.8 percent of its average volume over the last 100 days. The company's market cap stands at $17.8 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares increased by 26.7% to $0.12. Tivic Health Systems's trading volume hit 3.1 million shares by close, accounting for 112.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.7 million.
    • Evelo Biosciences (NASDAQ:EVLO) shares moved upwards by 23.26% to $0.16. Evelo Biosciences's trading volume hit 57.6 million shares by close, accounting for 1296.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $17.5 million.
    • Cano Health (NYSE:CANO) stock moved upwards by 15.94% to $1.45. At the close, Cano Health's trading volume reached 1.2 million shares. This is 27.5% of its average volume over the last 100 days. The company's market cap stands at $404.2 million.
    • Navidea Biopharmaceutical (AMEX:NAVB) shares moved upwards by 12.99% to $0.1. At the close, Navidea Biopharmaceutical's trading volume reached 7.8 million shares. This is 352.6% of its average volume over the last 100 days. The company's market cap stands at $3.5 million.
    • CalciMedica (NASDAQ:CALC) shares rose 12.32% to $5.65. The market value of their outstanding shares is at $31.9 million.

    Losers

    • Oncorus (NASDAQ:ONCR) stock fell 15.7% to $0.11 during Friday's after-market session. Trading volume for this security closed at 39.4 million, accounting for 2994.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million.
    • SCWorx (NASDAQ:WORX) shares fell 14.39% to $0.54. SCWorx's trading volume hit 1.9 million shares by close, accounting for 130.5% of its average volume over the last 100 days. The company's market cap stands at $7.0 million.
    • Mallinckrodt (AMEX:MNK) shares declined by 7.82% to $1.18. Mallinckrodt's trading volume hit 134.2K shares by close, accounting for 9.1% of its average volume over the last 100 days. The company's market cap stands at $15.5 million.
    • Accelerate Diagnostics (NASDAQ:AXDX) shares declined by 7.06% to $0.76. The market value of their outstanding shares is at $75.8 million.
    • Perspective Therapeutics (AMEX:CATX) shares declined by 6.84% to $0.66. The market value of their outstanding shares is at $184.8 million.
    • IMAC Hldgs (NASDAQ:BACK) shares decreased by 6.77% to $0.13. The market value of their outstanding shares is at $4.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AXDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AXDX
    $BACK
    $BFRI
    $CALC

    CompanyDatePrice TargetRatingAnalyst
    Perspective Therapeutics Inc.
    $CATX
    2/19/2026$16.00Overweight
    Piper Sandler
    CalciMedica Inc.
    $CALC
    1/29/2026Buy → Neutral
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    11/24/2025$12.00Buy
    Truist
    Perspective Therapeutics Inc.
    $CATX
    10/10/2025$14.00Buy
    BTIG Research
    Perspective Therapeutics Inc.
    $CATX
    3/13/2025$10.00Buy
    H.C. Wainwright
    Perspective Therapeutics Inc.
    $CATX
    3/7/2025$15.00Sector Outperform
    Scotiabank
    Perspective Therapeutics Inc.
    $CATX
    11/25/2024$24.00 → $5.00Buy → Neutral
    BofA Securities
    Perspective Therapeutics Inc.
    $CATX
    10/24/2024$20.00Buy
    UBS
    More analyst ratings

    $AXDX
    $BACK
    $BFRI
    $CALC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

    SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026. PresenterAbstract TitlePresentation DetailsThorvardur Halfdanarson, Mayo Clini

    3/17/26 4:45:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

    Lead program VMT-α-NET in neuroendocrine tumors continues to demonstrate a favorable tolerability profile with durable disease control and deepening of tumor response with longer follow-up, as reported at ASCO-GI 2026VMT-α-NET study on track to achieve nearly one year of follow-up in all 46 patients in Cohort 2 by mid-2026; analysis to inform patient selection strategy ongoingData across all dose levels in the VMT-α-NET program provide development optionality and support the build-out of a robust clinical evidence package for submission for presentation to more medical conferences and regulatory engagement in 2026Clinical updates for all three clinical programs are expected to be submitted f

    3/16/26 4:07:00 PM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BACK
    $BFRI
    $CALC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Hunt Jonathan Robert bought $22,295 worth of shares (11,000 units at $2.03), increasing direct ownership by 23% to 59,800 units (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/17/25 8:01:56 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    Director Williamson Robert F Iii bought $19,946 worth of shares (9,498 units at $2.10) (SEC Form 4)

    4 - Perspective Therapeutics, Inc. (0000728387) (Issuer)

    11/14/25 8:00:03 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    CHIEF BUSINESS OFFICER Roberts Eric W bought $7,675 worth of shares (2,500 units at $3.07) (SEC Form 4)

    4 - CalciMedica, Inc. (0001534133) (Issuer)

    9/22/25 9:35:04 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BACK
    $BFRI
    $CALC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Perspective Therapeutics with a new price target

    Piper Sandler initiated coverage of Perspective Therapeutics with a rating of Overweight and set a new price target of $16.00

    2/19/26 7:52:02 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    CalciMedica downgraded by H.C. Wainwright

    H.C. Wainwright downgraded CalciMedica from Buy to Neutral

    1/29/26 7:00:08 AM ET
    $CALC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist resumed coverage on Perspective Therapeutics with a new price target

    Truist resumed coverage of Perspective Therapeutics with a rating of Buy and set a new price target of $12.00

    11/24/25 9:17:24 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    $AXDX
    $BACK
    $BFRI
    $CALC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wolf Lisa G

    4 - Tivic Health Systems, Inc. (0001787740) (Issuer)

    3/19/26 9:14:41 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Weber Kevin Daniel

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:33:07 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)

    4 - Biofrontera Inc. (0001858685) (Issuer)

    3/6/26 9:31:43 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BACK
    $BFRI
    $CALC
    Leadership Updates

    Live Leadership Updates

    View All

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer

    SEATTLE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced the appointment of Joel Sendek as the Company's Chief Financial Officer, effective today. Mr. Sendek brings extensive experience in senior corporate roles in biotech finance and as a highly respected senior equity research analyst at a number of leading firms. Mr. Sendek previously served as CFO at four biotech companies: Dewpoint Therapeutics, Sema4, Spero Therapeutics, and Forward Pharma. He has a successful track record in corporate finance, having completed

    9/4/25 7:00:00 AM ET
    $CATX
    Medical/Dental Instruments
    Health Care

    SCWorx Corp. Appoints New Chief Technology Officer to Accelerate Innovation in Healthcare Data Solutions

    Tampa, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (NASDAQ:WORX), a leading provider of data management and software solutions for the healthcare industry, today announced the appointment of Anders Ohlsson, a seasoned technology executive, as its new Chief Technology Officer (CTO). This strategic hire underscores SCWorx's commitment to advancing its data platform and expanding its suite of data management and software solutions for healthcare providers. Mr. Ohlsson has over 25 years of experience in software engineering, cloud infrastructure, and machine learning applications. Prior to joining SCWorx, he held senior leadership roles at WideOrbit, where he spearheaded the developm

    9/3/25 11:44:49 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AXDX
    $BACK
    $BFRI
    $CALC
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/25/26 4:25:57 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/20/26 5:15:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by Biofrontera Inc.

    10-K - Biofrontera Inc. (0001858685) (Filer)

    3/19/26 4:15:56 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AXDX
    $BACK
    $BFRI
    $CALC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AXDX
    $BACK
    $BFRI
    $CALC
    Financials

    Live finance-specific insights

    View All

    Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

    Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio

    3/19/26 9:25:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

    WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi

    3/9/26 5:25:00 PM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth

    Fourth quarter results represent highest quarterly revenue in Company's historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter ended December 31, 2025. Fourth quarter revenues are expected to be between $17.0 million and $17.5 million, representing the highest quarterly revenue in the Company's history. For the full year 2

    1/13/26 8:30:00 AM ET
    $BFRI
    Biotechnology: Pharmaceutical Preparations
    Health Care